Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Multicentre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects

NCT04217590 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04217590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04217590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Multicentre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
November 16, 2020
Completion date
January 3, 2022
Enrollment
134 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia